About
5
Publications
583
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
62
Citations
Citations since 2017
Introduction
Kunal Kapoor currently works at the Department of Immunology, University of Manitoba. Kunal does research in Human Biology, Immunology and Gastroenterology. Their most recent publication is ' CHROMOFUNGIN DECREASES INTESTINAL INFLAMMATION AND REGULATES DENDRITIC CELLS MARKERS'.
Skills and Expertise
Publications
Publications (5)
Background:
Chromofungin (CHR: chromogranin-A 47-66) is a chromogranin-A derived peptide with anti-inflammatory and anti-microbial properties. Ulcerative colitis (UC) is characterized by a colonic decrease of CHR and a dysregulation of dendritic CD11c+ cells.
Aim:
To investigate the association between CHR treatment and dendritic cells (DCs)-rel...
The pro-inflammatory mediator receptor activator of nuclear factor-kappa B ligand (RANKL) plays a significant role in the development of rheumatoid arthritis; however, its role in inflammatory bowel disease is unknown. Genome-wide association meta-analysis for Crohn’s disease (CD) identified a variant near the TNFSF11 gene that encodes RANKL and CD...
Background
Ulcerative colitis (UC) is characterized by altered levels of chromogranin-A (CHGA) and a dysregulation of dendritic cells (DCs). CHGA, a prohormone protein, can be cleaved into several bioactive peptides including chromofungin (CHR: CHGA47-66) encoded by CHGA Exon-IV. Previously, we demonstrated that CHR is reduced in active UC patients...
We have previously shown that poly (ADP-ribose) polymerase (PARP)-1 gene deletion in mice provide robust protection against lung inflammation in the context of asthma and acute lung injury. Olaparib is a potent new generation PARP inhibitor that has been approved for human testing in cancer patients. The present work was designed to evaluate its be...
We have previously shown that PARP-1 inhibition provides protection against lung inflammation in the context of asthma and acute lung injury. Olaparib is a potent new generation PARP inhibitor that has been approved for human testing. The present work was designed to evaluate its beneficial potential against LPS-induced acute lung injury and acute...
